By: K. Papadimitriou MD, PhD, M. Rasschaert MD, J. Van den Brande MD, M. Peeters MD, PhD
A large body of trials, including large adjuvant phase III trials up to early phase trials was presented during the 2015 European Cancer Congress (ECC). Immunotherapy, was once more in the center of the scientific interest for different types of cancer and settings. This report will focus on some of the key studies presented during the meeting, referring to gastrointestinal cancer.
(BELG J MED ONCOL 2015;9:217–21)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
